Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $944.88 MXN
Change Today 0.00 / 0.00%
Volume 0.0
TEVAN On Other Exchanges
New York
Tel Aviv
As of 4:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

teva pharmaceutical-sp adr (TEVAN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/16/15 - $1,016
52 Week Low
06/5/14 - $657.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

teva pharmaceutical-sp adr (TEVAN) Details

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers generic or branded generic medicines; specialized products, such as sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances; and active pharmaceutical ingredients. The Specialty Medicines segment provides branded specialty medicines for use in central nervous system and respiratory indications, as well as the women’s health, oncology, and other specialty businesses. Its products in the central nervous system area comprise Copaxone for multiple sclerosis; Azilect for the treatment of Parkinson’s disease; Nuvigil and Provigil to treat excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorders; Fentora/Effentora and Actiq to treat pain in opioid-tolerant adult patients with cancer; Zecuity for the treatment of migraine in adults; and Amrix for muscle spasm in acute, painful, and musculoskeletal conditions. This segment’s products in the respiratory market include ProAir, QVAR, and Duoresp Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Treanda, Trisenox, Granix, Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, and Eporatio products in the oncology market. This segment also offers a portfolio of products in the women’s health category, which includes ParaGard, Plan B One-Step, and Zoely. In addition, the company provides branded over-the-counter medicines in the categories of cough/cold and allergy, digestive wellness, vitamins, minerals and supplements, analgesics, and skin medications; and sells third-party products, such as medical devices and other miscellaneous items. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Petach Tikva, Israel.

43,009 Employees
Last Reported Date: 02/9/15
Founded in 1901

teva pharmaceutical-sp adr (TEVAN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

teva pharmaceutical-sp adr (TEVAN) Key Developments

Teva Pharmaceutical Industries Limited Presents Results of Chronic Migraine Phase 2B Study Evaluating the Efficacy and Safety, Versus Placebo, of Two Doses of TEV-48125

Teva Pharmaceutical Industries Ltd. announced the presentation of further data from its chronic migraine phase 2b study evaluating the efficacy and safety, versus placebo, of two doses of TEV-48125, an anti-calcitonin gene-related peptide (CGRP) ligand monoclonal antibody. These data will be presented on May 15th, 2015, as a late breaking oral presentation at the 17th Congress of the International Headache Society (IHC 2015). Both assessed doses of TEV-48125 (loading of 675 followed by monthly injections of 225 mg or 900 mg), were significantly superior to placebo in reducing, relative to baseline, the number of hours with headache (primary endpoint — p < 0.05 and p < 0.01). TEV-48125 also significantly decreased the number of headache days of moderate or severe intensity in month 3 (secondary endpoint — p < 0.05 and p < 0.05). A priori analyses indicated that separation from placebo was seen after a single dose of therapy, and exploratory analyses also showed both doses of TEV-48125 separating from placebo as early as one week post-treatment: decrease of headache hours from baseline (primary endpoint) at week 1 was -9.1 for TEV-48125 675/225mg (p = 0.03), -11.4 for 900 mg (p = 0.003), and -2.8 for placebo. This benefit increased progressively at 1 month, with decreases of -44.1 hours for 675/225 mg (p = 0.003), -56.82 hours for 900 mg (p < 0.001) and -18.1 hours for placebo. At three months decreases were -59.8 for 675/225 mg (p = 0.04) -67.5 for 900 mg (p = 0.006) and -37.1 for placebo. Similar decreases were seen for number of moderate/severe headache days (secondary endpoint), where both doses separated from placebo at 2 weeks, and maintained at 1 month and 3 months. Additionally, TEV-48125 was associated with a significant decrease in the consumption of acute migraine medications. No treatment-related serious adverse events were reported with use of TEV-48125. Most common AEs were mild injection-site pain or pruritus. No other relevant differences in the rate of treatment-emergent adverse events occurred for those receiving TEV-48125 doses relative to placebo. Antibodies anti-drug were the lowest in class up to this point (1.1% for TEV-48125 in this trial, and present before drug exposure). Furthermore, over half of the patients in both dose groups experienced a 50% or more decrease in headache frequency (p<0.01 for both doses vs. placebo), nearly one third of patients in both dose groups had a 75% decrease in headache frequency (p < 0.05 for both doses) and around 15% were totally free of headaches at month three. The study was conducted amongst 264 highly severe chronic migraine patients who suffered from a mean of approximately 162 headache hours per month (approx. 17 migraine days per month, and around 21 days of headache per month). They had suffered from migraines for mean period of 18 years. Amongst the most affected of these patients (upper third), 42% reverted to episodic migraine in the 675/225 mg arm and 43% in the 900 mg arm, vs 22% in placebo. Overall, by the end of the study nearly 60% of patients reverted from chronic to episodic migraine. The study was a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group, multi-dose study comparing TEV-48125 with placebo. Following a 28 day run-in period, qualifying patients (n=264) were randomized to one of three treatment arms receiving high dose TEV-48125 (900mg), low dose TEV-48125 (675/225 mg) or placebo, given subcutaneously once a month for three months. Subjects had their headache and health information captured daily during the entire study, using an electronic headache diary system. The study was conducted in approximately 60 centers in the USA. TEV-48125 (formerly LBR-101/RN-307) is a monoclonal antibody that binds to calcitonin gene-related peptide (CGRP), a well-validated target in migraine. CGRP signaling may be disrupted by targeting the ligand itself or its receptor. Teva’s approach targets the ligand, allowing for some CGRP signaling during therapy. This avoids the potential effects of a long-term total disruption to the normal physiological functions of the CGRP system, which are unknown. TEV-48125, administered as a once-monthly subcutaneous injection, is being developed for both chronic migraine and high frequency episodic migraine. Data from a recently announced Phase IIb study for the prevention of high frequency episodic migraine, also demonstrated the efficacy and safety of two doses of TEV-48125 in 300 patients. Findings were consistent with the chronic migraine data achieving highly significant reductions in mean monthly migraine days after a single dose, establishing TEV-48125 as the first, and only, treatment to date to meet efficacy and safety endpoints in trials of both chronic and episodic migraine and across multiple doses.

Mylan May Consider Buying Teva

Mylan N.V. (NasdaqGS:MYL) is not willing to sell itself to Teva Pharmaceutical Industries Limited (NYSE:TEVA), Mylan’s Executive Chairman, Robert Coury said. The official added that the company would consider buying that company down the road. The company has been steadfast in its refusal to combine with Teva and is instead encouraging shareholders to support its own $34 billion unsolicited offer for over-the-counter Perrigo Company Public Limited Company (NYSE:PRGO). Teva made an unsolicited $40 billion bid for Mylan in April 2015, and it was rejected. Teva said recently that it will move ahead with its plans to acquire Mylan if the Perrigo deal is not completed.

Teva Pharmaceutical Industries Limited Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM

Teva Pharmaceutical Industries Limited Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:40 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Eyal Desheh, Chief Financial Officer and Group Executive Vice President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEVAN:MM $944.88 MXN 0.00

TEVAN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.03 USD -0.31
AbbVie Inc $65.48 USD -0.17
Baxter International Inc $67.37 USD -0.17
Eli Lilly & Co $74.30 USD +0.03
Medtronic PLC $77.82 USD -0.59
View Industry Companies

Industry Analysis


Industry Average

Valuation TEVAN Industry Range
Price/Earnings 19.0x
Price/Sales 2.6x
Price/Book 2.3x
Price/Cash Flow 21.2x
TEV/Sales 2.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TEVA PHARMACEUTICAL-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at